Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

August 23, 2024

Study Completion Date

May 28, 2025

Conditions
Carcinoma
Interventions
DRUG

osimertinib

osimertinib (80 mg oral OD).

DRUG

savolitinib

savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)

DRUG

placebo

placebo to osimertinib (oral OD)

Trial Locations (90)

112

Research Site, Taipei

300

Research Site, Hsinchu

333

Research Site, Taoyuan District

402

Research Site, Taichung

2100

Research Site, København Ø

2730

Research Site, Herlev

4700

Research Site, Næstved

5000

Research Site, Odense

7100

Research Site, Vejle

9100

Research Site, Aalborg

10002

Research Site, Taipei

10043

Research Site, Orbassano

10408

Research Site, Goyang-si

11220

Research Site, Brooklyn

13620

Research Site, Seongnam-si

13915

Research Site, Marseille

14004

Research Site, Córdoba

15232

Research Site, Pittsburgh

16247

Research Site, Suwon

19111

Research Site, Philadelphia

20014

Research Site, Donostia / San Sebastian

20016

Research Site, Washington D.C.

20133

Research Site, Milan

20141

Research Site, Milan

21079

Research Site, Dijon

21201

Research Site, Baltimore

23561

Research Site, New Taipei City

28041

Research Site, Madrid

28046

Research Site, Madrid

29010

Research Site, Málaga

35033

Research Site, Rennes

35128

Research Site, Padua

37019

Research Site, Peschiera del Garda

40705

Research Site, Taichung

43126

Research Site, Parma

44093

Research Site, Nantes

46026

Research Site, Valencia

50009

Research Site, Zaragoza

50134

Research Site, Florence

55905

Research Site, Rochester

70403

Research Site, Tainan City

75020

Research Site, Paris

75248

Research Site, Paris

83100

Research Site, Avellino

83301

Research Site, Kaohsiung City

90024

Research Site, Los Angeles

92093

Research Site, La Jolla

95817

Research Site, Sacramento

98109

Research Site, Seattle

100000

Research Site, Hà Nội

110085

Research Site, New Delhi

560064

Research Site, Bangalore

600035

Research Site, Chennai

700000

Research Site, Ho Chi Minh City

700160

Research Site, Kolkata

7500713

Research Site, Santiago

7520349

Research Site, Santiago

8420383

Research Site, Santiago

02215

Research Site, Boston

14784-400

Research Site, Barretos

80810-050

Research Site, Curitiba

74093-300

Research Site, Goiânia

90540-140

Research Site, Porto Alegre

90610-000

Research Site, Porto Alegre

22271-110

Research Site, Rio de Janeiro

41950-640

Research Site, Salvador

15090-000

Research Site, São José do Rio Preto

01246-000

Research Site, São Paulo

01509-900

Research Site, São Paulo

T2N 5G2

Research Site, Calgary

T6G 1Z2

Research Site, Edmonton

L3Y 2P9

Research Site, Newmarket

M2K 1E1

Research Site, North York

M4N 3M5

Research Site, Toronto

M5G 2M9

Research Site, Toronto

06132

Research Site, Perugia

812-8582

Research Site, Fukuoka

730-8518

Research Site, Hiroshima

920-8641

Research Site, Kanazawa

464-8681

Research Site, Nagoya

951-8566

Research Site, Niigata

003-0804

Research Site, Sapporo

589-8511

Research Site, Sayama

411-8777

Research Site, Sunto-gun

641-8510

Research Site, Wakayama

241-0815

Research Site, Yokohama

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Hutchison Medipharma Limited

INDUSTRY

lead

AstraZeneca

INDUSTRY